Miransertib

DRUG2 trials

Sponsors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), Merck Sharp & Dohme LLC

Conditions

PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus SyndromePIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)

Phase 1

Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)

TerminatedNCT03094832

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome

Start: 2017-05-16End: 2022-04-11Updated: 2023-04-13

Phase 2

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

Active, not recruitingNCT04980872

Merck Sharp & Dohme LLCPIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)

Start: 2021-11-02End: 2030-02-07Target: 60Updated: 2025-02-07

Related Papers

Safety findings from the phase 1/2 MOSAIC study of miransertib for patients with PIK3CA-related overgrowth spectrum or Proteus syndrome.

2025-07-251 citations

Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome.

2021-02-2756 citations